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Abstract
Background Nephronophthisis is an autosomal recessive ciliopathy and important cause of end-stage renal disease (ESRD)
in children and young adults. Diagnostic delay is frequent. This study investigates clinical characteristics, initial symp-
toms, and genetic defects in a cohort with nephronophthisis-related ciliopathy, to improve early detection and genetic
counseling.
Methods Forty patients from 36 families with nephronophthisis-related ciliopathy were recruited at university medical
centers and online. Comprehensive clinical and genotypic data were recorded. Patients without molecular diagnosis were
offered genetic analysis.
Results Of 40 patients, 45% had isolated nephronophthisis, 48% syndromic diagnosis, and 7% nephronophthisis with
extrarenal features not constituting a recognizable syndrome. Patients developed ESRD at median 13 years (range 5–47).
Median age of symptom onset was 9 years in both isolated and syndromic forms (range 5–26 vs. 5–33). Common
presenting symptoms were fatigue (42%), polydipsia/polyuria (33%), and hypertension (21%). Renal ultrasound showed
small-to-normal-sized kidneys, increased echogenicity (65%), cysts (43%), and abnormal corticomedullary
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differentiation (32%). Renal biopsies in eight patients showed nonspecific signs of chronic kidney disease (CKD).
Twenty-three patients (58%) had genetic diagnosis upon inclusion. Thirteen of those without a genetic diagnosis gave
consent for genetic testing, and a cause was identified in five (38%).
Conclusions Nephronophthisis is genetically and phenotypically heterogeneous and should be considered in children and
young adults presenting with persistent fatigue and polyuria, and in all patients with unexplained CKD. As symptom
onset can occur into adulthood, presymptomatic monitoring of kidney function in syndromic ciliopathy patients should
continue until at least age 30.
Keywords Nephronophthisis . Pediatric kidney disease . Ciliopathy . Clinical registry . Gene-phenotype association
Introduction
Nephronophthisis (NPH) is an autosomal recessive kidney
disease that is responsible for up to 15% of pediatric patients
with end-stage renal disease (ESRD) [1–3]. In The
Netherlands, this corresponds to an estimated one to five
children with ESRD per year [4]. NPH is characterized by a
renal concentration defect, chronic tubulointerstitial nephritis,
renal cysts in 50% of patients, and progression to ESRD
before age 30 years [5–7]. Three clinical subtypes are recog-
nized based on age of onset. The most prevalent form, juve-
nile NPH, results in ESRD at a median age of 13 years [3,
7–9]. NPH can occur in an isolated form and, in 10 to 15% of
cases, as part of a multisystem disorder, for example Senior-
Løken syndrome and Joubert syndrome. Both isolated and
syndromic NPH are caused by mutations in genes encoding
proteins that localize to primary cilia. These mutations result
in structural and functional ciliary defects, and disruption of
essential ciliary and nuclear signaling pathways. Hence, NPH
is considered a ciliopathy.
The diagnosis of NPH is based on clinical findings,
renal ultrasound findings, and a family history compatible
with autosomal recessive inheritance. The average diag-
nostic delay in isolated NPH is 3.5 years because of non-
specific presenting symptoms including polydipsia and
polyuria, secondary enuresis, growth retardation, and ane-
mia refractory to iron therapy [7]. In addition, causal mu-
tations in one of the 20 NPH-associated genes are detect-
ed in less than 50% of patients [10–12]. Although recent
progress has been made in characterizing the clinical
spectrum of NPH [6, 7, 13, 14], the absence of solid
genotype-phenotype correlations currently limits prognos-
tic counseling of NPH patients. Therefore, analysis of
presenting symptoms, renal and extrarenal phenotypes,
and associated genetic defects in a well-defined popula-
tion of NPH patients is warranted.
Here we report clinical characteristics and genetic find-
ings in a cohort of 40 Dutch patients from 36 families
with a nephronophthisis-related ciliopathy (NPH-RC).
We assess progression of chronic kidney disease (CKD)
in isolated and syndromic forms of NPH and discuss the
initial signs and symptoms of kidney disease that could
point towards NPH in an early disease stage. Renal and
extrarenal phenotypes and associated genetic defects are
analyzed. Finally, our results suggest the limited diagnos-
tic value of a renal biopsy in advanced stages of CKD and
point towards the utility of early molecular testing in di-
agnostics of NPH.
Methods
Patients
Patients were recruited at all eight university medical cen-
ters in The Netherlands, via the Dutch Kidney Patient
Association and the Dutch Joubert Syndrome Patient and
Parents’ Network, and via the webpage www.kouncil.nl.
Patients were included in the AGORA (Aetiologic
research into Genetic and Occupational/environmental
Risk factors for Anomalies in children) data- and biobank
from March 2014 until May 2017 at the Department of
Genetics and the Department of Pediatric Nephrology of
the University Medical Center Utrecht, the Department of
Human Genetics of the Radboudumc Nijmegen, and the
Department of Nephrology of the VU University Medical
Center Amsterdam. Approval by the regional Committee
on Research involving human subjects (CMO Arnhem-
Nijmegen 2006/048) was obtained. Informed consent
was available for all subjects for access to medical re-
cords, DNA testing, and/or collection of biomaterial in-
cluding urine, fibroblasts, and/or deciduous teeth.
Inclusion criteria were a molecularly confirmed diag-
nosis of NPH-RC or suspected NPH-RC. NPH-RC was
defined as isolated NPH, NPH with extrarenal features
that do not constitute a recognizable syndrome, and
syndromic NPH. Suspected NPH-RC was based on the
presence of CKD stages 2–5 in all patients [15], a family
history compatible with autosomal recessive inheritance,
and additional extrarenal features associated with a
ciliopathy and/or clinical characteristics of NPH including
signs of a renal concentration defect (e.g., polyuria), renal
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ultrasound showing parenchymal damage (e.g., increased
echogenicity) but absence of congenital anomalies of the
kidneys and urinary tract that could explain the pheno-
type, urinalysis showing absence of hematuria, erythro-
cyte casts and proteinuria in the nephrotic range, absence
of recurrent urinary tract infections, and exclusion of oth-
er causes of early-onset renal failure. Cases in which the
clinical diagnosis was ambiguous were discussed with a
pediatric nephrologist (M. L.) and a clinical geneticist (N.
K.) until consensus was reached. We included five pa-
tients with Bardet-Biedl syndrome and a nephronophthisis
phenotype; however, the classification of Bardet-Biedl
syndrome as NPH-RC is not consistent across literature
[6, 11]. Siblings of patients with molecularly confirmed
NPH-RC who had the same biallelic mutations in an
NPH-RC-associated gene and who showed some but not
all clinical features were included for the analysis of ini-
tial phenotypic features of NPH. In addition to 40 patients
with NPH-RC, we included 12 patients with a ciliopathy
and renal features that did not fulfill clinical criteria of
NPH to assess the phenotypic spectrum of renal
ciliopathies.
The Nephronophthisis Registry
To record detailed clinical and genetic data from patients
w i t h NPH -RC , w e d e v e l o p e d a mu l t i c e n t e r
Nephronophthisis Registry using Castor EDC (Castor
Electronic Data Capture, Ciwit BV, Amsterdam,
The Netherlands). Access to electronic medical records
or paper copies of medical records was requested for all
patients. For standardized data collection, a set of clinical
parameters and definitions was established by a team of
clinical experts from relevant fields including pediatric
nephrology, clinical genetics, and clinical molecular ge-
netics. Consensus was reached on all parameters. Human
Phenotype Ontology (HPO) terms were used for most of
the clinical terms recorded to phenotype the patients,
thereby also providing a basis for future integration with
clinical data from other nephronophthisis registries and
for clinical matching of patients in HPO-centered regis-
tries of rare diseases [16]. Case report forms were struc-
tured in categories including medical history, physical ex-
amination, ophthalmological examination, and genetic
analysis. For longitudinal data, we developed report forms
for laboratory results, medication, physical re-examina-
tion, histological examination, and imaging. Syndrome
diagnoses were based on clinical data on renal and
extrarenal phenotypes (e.g., presence of molar tooth sign
on brain imaging in Joubert syndrome) according to inter-
nationally recognized diagnostic criteria [17–20], in com-
bination with the assessment of the referring physician.
Genetic analyses
Of 17 patients without a molecular diagnosis upon inclusion, 13
patients from 12 families gave consent for genetic testing.
Targeted deletion/duplication analysis was performed to assess
the occurrence of NPHP1 deletions in patients with isolated
NPH, Senior-Løken syndrome, and Joubert syndrome, and to
assess copy number variations in ciliary genes in which we
identified single heterozygous point mutations (Supplementary
Methods S1). Targeted next-generation sequencing using a gene
panel containing 15 genes associated with NPH was performed
in one patient (10:44). Whole-exome sequencing
(Supplementary Methods S2) was subsequently performed in
this patient and 10 additional patients with no deletion or a
heterozygous deletion in NPHP1, including a patient with
Bardet-Biedl-like syndrome in whom biallelicNPHP1 deletions
were unlikely to be causal.
Statistical analyses
Clinical and genetic data from the Nephronophthisis Registry
were exported to Excel and analyzed using GraphPad Prism
(version 7.02).
Results
Phenotypic variability in renal ciliopathies
Forty patients from 36 families with NPH-RC were recruited,
including patients with isolatedNPH (n = 18), Joubert syndrome
(n = 8), Bardet-Biedl syndrome (n = 5), Senior-Løken syndrome
(n = 4), cranioectodermal dysplasia (n = 2), and NPH-RC phe-
notypes that did not constitute a recognizable syndrome (n = 3)
(Fig. 1). Twenty-two out of 40 patients (55%) had extrarenal
ciliopathy-associated features including impaired vision (16/
40; 40%), oculomotor abnormalities (10/33; 30%), and devel-
opmental delay (13/36; 36%), indicating enrichment of
syndromic forms of NPH-RC in our cohort (Supplementary
Table S1). Table 1 depicts the frequency of occurrence of clinical
features per causative gene for 40 patients.
Patients developed ESRD at a median age of 13 years
(range 5–47 years). The median age of symptom onset was
9 years in both isolated and syndromic forms of NPH (range
5–26 vs. 5–33 years respectively). Median time between re-
ported symptom onset and ESRDwas 1 year (range 0–8 years)
in patients with isolated NPH (n = 11) and 5.5 years (range 0–
14 years) in patients with syndromic forms of NPH (n = 4).
Four out of 18 patients with isolated NPH (22%) did not yet
have ESRD at the time of inclusion (median age 21 years;
range 17–41 years), although two patients had at least CKD
stage 3. In contrast, 10/20 patients with syndromic forms of
NPH (50%) did not have ESRD at the time of inclusion
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(median age 15.5 years; range 10–25 years) and three patients
had at least CKD stage 3. More longitudinal data will be
collected to determine the rate of CKD progression in patients
with isolated and syndromic forms of NPH.
To evaluate the range of renal ciliopathy-associated pheno-
types, we included 12 patients with a renal ciliopathy without
sufficient evidence for NPH. Phenotypes included perinatally
lethal renal cystic hypodysplasia and renal insufficiency with
proteinuria (Supplementary Results S1 and Supplementary
Table S2).
Fatigue and polyuria are presenting symptoms
of NPH
To assess presenting symptoms of NPH, we reviewed medical
records and conducted patient interviews. Presenting symp-
toms were documented for 24/40 patients. The most frequent-
ly reported initial signs and symptoms were fatigue (10/24;
42%), polydipsia and polyuria (8/24; 33%) and hypertension
(5/24; 21%) (Fig. 2 and Supplementary Table S3). Anemia
(2/24; 8%), growth retardation (2/24; 8%), enuresis (2/24;
8%), and uremic symptoms (1/24; 4%) occurred less frequent-
ly. Novel reported presenting symptoms included muscle
cramps and injuries (n = 2), dizziness (n = 1), red patches on
the skin (n = 1), and weight loss (n = 1). In addition, a patient
with Joubert syndrome caused by NPHP1 mutations (34:73)
reported muscle cramps after NPH was diagnosed. Based on
these findings, persistent fatigue and muscle complaints in
children should prompt evaluation of kidney function in addi-
tion to the classic presenting symptoms of NPH.
Fig. 1 Relative frequencies of (nephronophthisis-related ciliopathy)
NPH-RC phenotypes in the cohort. NPH isolated nephronophthisis,
JBTS Joubert syndrome, BBS Bardet-Biedl syndrome, SLS Senior-
Løken syndrome, CED cranioectodermal dysplasia
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Increased echogenicity is a more prevalent finding
than renal cysts in NPH-RC
Overall occurring symptoms were analyzed in 40 patients
with NPH-RC. The most frequently reported symptoms were
polydipsia and polyuria (18/25; 72% and 15/25; 60%, respec-
tively) and enuresis (4/19; 21%) (Table 2 and Supplementary
Table S3). Fifteen out of 23 patients (65%) had normal-sized
kidneys on renal ultrasound and eight patients (35%) had at
least one small kidney (size < 5th percentile) (reference
values: [21, 22]). Small- to normal-sized kidneys is a typical
finding in NPH [6, 7, 23]. Additional ultrasound findings
included increased echogenicity (17/26; 65%), renal cysts
(13/30; 43%), and abnormal corticomedullary differentiation
(7/22; 32%). Increased echogenicity was the most prevalent
finding on renal ultrasound and could therefore be considered
a more sensitive finding for nephronophthisis than renal
cysts.
Histological findings are frequently nonspecific
in NPH
Renal biopsy was performed in 8/40 patients. Insufficient
material was obtained from two patients, resulting in a
second biopsy for one patient. Tubulointerstitial nephritis
was a finding in 4/7 biopsies and tubular atrophy in 3/7.
Renal cysts were reported in none of the patients. Instead,
glomerulosclerosis was seen in 5/7 biopsies. Biopsies were
taken in advanced stages of NPH (CKD stage ≥ 3 for all
patients except patient 11:45), when differentiating find-
ings such as thickening of tubular basement membranes
and cysts on the corticomedullary border were expected
to be no longer detectable. These findings suggest that
the diagnostic value of a renal biopsy is limited in ad-
vanced stages of CKD, which is often already present
when the diagnosis of NPH is first suspected.
NPHP1 mutations in 38% of tested patients
Twenty-three out of 40 patients (58%) had a (likely) molecular
diagnosis at the time of inclusion (Supplementary Table S4).
We performed genetic testing for 13 patients from 12 families
without a molecular diagnosis, including genotyping, bioin-
formatics analysis, and/or functional assays for the interpreta-
tion of genetic variants (Fig. 3a). A biallelic mutation in
NPHP1 was detected in five out of 13 patients (38%), of
whom two patients had a homozygous deletion and three pa-
tients had a compound heterozygous deletion and mutation
(Table 3). Consequently, NPHP1was the most frequently mu-
tated gene in our cohort (16/36 patients (44%); Fig. 3b), which
is consistent with literature [10].
Additional biallelic variants were detected in TMEM67
in one patient with Bardet-Biedl-like syndrome (23:58).
Two unrelated patients with Joubert syndrome (1:34 and
5:38) harbored a compound heterozygous known patho-
genic variant and the same missense variant of unknown
significance (c.[628T>C] p.[Ser210Pro]) in TMEM67, sug-
gesting a possible founder effect. This variant represents a
novel candidate variant for NPH-RC. Interestingly, the lat-
ter two patients had progressive liver fibrosis, liver func-
tion abnormalities, and hepatomegaly, which is consistent
with reports of liver involvement in patients with muta-
tions in TMEM67 [6, 14].
Fig. 2 Presenting signs and
symptoms of nephronophthisis.
Presenting signs and symptoms of
nephronophthisis (NPH) by
frequency of occurrence. Data
was available for 24 patients. For
ten patients, more than one
presenting sign or symptom was
reported
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Gene-phenotype associations
NPHP1 (n = 16)
Biallelic mutations in NPHP1 were detected in patients with
isolated NPH (n = 12), Joubert syndrome (n = 2), and Senior-
Løken syndrome (n = 2). Median reported age of symptom
onset was 9 years (range 6–26 years) and median age of
ESRD was 14 years (range 7–28 years). Patients with
NPHP1mutations had higher reported frequencies of polyuria
(9/10; 90%), polydipsia (8/10; 80%), and enuresis (3/8; 38%)
compared to all patients. Strikingly, renal cysts were present in
only 4/12 patients (33%) with NPHP1 mutations, while
hype r e chogen i c i t y ( 7 / 10 ; 70%) and abno rma l
corticomedullary differentiation (3/8; 38%) were reported
more frequently compared to the cohort average. Extrarenal
manifestations included visual impairment (3/16; 19%)—
mainly retinitis pigmentosa (n = 2)—obesity (n = 2),
Fig. 3 Clinical and genetic
characterization of the cohort. a
Genetic diagnostic testing
strategy. (1) Targeted next-
generation sequencing included a
multi-gene panel and/or whole-
exome sequencing. b Prevalence
of causal genes per
nephronophthisis-related
ciliopathy (NPH-RC) phenotype.
NPH isolated nephronophthisis,
JBTS Joubert syndrome, BBS
Bardet-Biedl syndrome, SLS
Senior-Løken syndrome, CED
cranioectodermal dysplasia
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congenital heart disease (n = 1), oculomotor apraxia (n = 1),
and developmental delay (n = 1).
NPHP4 (n = 3)
Three patients with mutations in NPHP4 presented with iso-
lated NPH. Median reported age of symptom onset was
16 years (range 8–24 years). One patient already had ESRD
when the diagnosis was made at age 8 years. The other two
patients had not yet developed ESRD at age 19 and 41 years
respectively. The renal phenotype was characterized by poly-
dipsia and/or polyuria (n = 2) and increased echogenicity (n =
2), cysts (n = 1), and abnormal corticomedullary differentia-
tion (n = 1) on renal ultrasound. There were no extrarenal fea-
tures reported in patients with mutations in NPHP4.
WDR35 (n = 3)
Three patients had biallelic mutations inWDR35; two patients
(siblings) had cranioectodermal dysplasia (CED) and one pa-
tient had a ciliopathy phenotype that did not constitute a rec-
ognizable syndrome. The patients with CED did not yet de-
velop ESRD at age 17 (CKD stage 3) and 12 years (CKD
stage 1–2) respectively. Their phenotype was characterized
by a narrow thorax and short limbs. The patient without a
syndrome diagnosis developed ESRD at age 12 years.
Extrarenal manifestations comprised retinitis pigmentosa, oc-
ulomotor abnormalities, autism spectrum disorder, liver cir-
rhosis, polydactyly, and obesity.
BBS1 (n = 2)
Biallelic mutations in BBS1 were identified in two patients
(siblings) with Bardet-Biedl syndrome and slowly progressive
kidney disease. The patients had not yet developed ESRD at
age 20 (CKD stage 1–2) and 16 years (CKD stage 2) respec-
tively. Kidney cysts were present in the eldest patient. Both
had visual impairment, developmental delay, and obesity.
Other genes
Biallelic mutations in the ciliopathy-associated genes AHI1,
BBS10, IQCB1, and OFD1 were identified in single patients.
Renal and extrarenal findings associated with mutations in
these genes are summarized in Tables 1 and 2.
Discussion
We describe a cohort of 40 Dutch patients with NPH-RC in-
cluded in the Nephronophthisis Registry over a period of
3 years (2014 to 2017). This study represents a comprehensive
characterization of renal and extrarenal ciliopathy-associated
features and associations with genetic findings in a well-
defined population. Increased echogenicity was a more prev-
alent finding on renal ultrasound than kidney cysts (65 vs.
43%), especially in patients with mutations in NPHP1 (70
vs. 33%). This finding is consistent with literature that de-
scribes increased echogenicity and a loss of corticomedullary
differentiation on renal ultrasound in 78% of pediatric patients,
and cystic lesions in only 51% [6]. Increased echogenicity is
considered a sensitive marker for early stages of CKD in chil-
dren, although it is not specific for NPH [11]. With the
Nephronophthisis Registry, we aim to contribute to the grow-
ing understanding of NPH-RC phenotypes [6, 7, 13, 14],
which will in turn advance diagnostics and genetic counseling.
The median age of NPH symptom onset in the cohort pre-
sented here was 9 years (range 5–33 years), which is above the
age of 6 years reported in the literature [3]. In addition, while
the median age at which ESRD was reached (13 years) was
consistent with literature [3, 7–9], the age of ESRD onset varied
from 5 to 47 years. Four patients with mutations in NPHP1
developed ESRD at or after age 20 years. A recent report of
NPHP1-associated adult onset NPH also supports a later onset
of NPH than was previously assumed [26]. This is important
because monitoring of renal function in syndromic ciliopathy
patients is often discontinued if no kidney disease is present at
age 18 years. Based on the range of reported age of onset in our
cohort, presymptomatic monitoring of renal function should be
performed annually in ciliopathy patients until at least age
30 years. If CKD is established, the monitoring frequency can
be adjusted according to the rate of kidney function decline.
Individual patient reports demonstrated diagnostic delay in
patients with isolated NPH. For example, a patient with Senior-
Løken syndrome caused by NPHP1mutations (11:45) had sec-
ondary enuresis nocturna for at least 1 year prior to her diagno-
sis at age 13. Around the time of diagnosis, a renal biopsy
showed chronic tubulointers t i t i a l nephr i t i s and
glomerulosclerosis. While typical histologic findings, including
tubulointerstitial fibrosis, thickened and disrupted tubular base-
ment membrane, and sporadic corticomedullary cysts have
been described in NPH [7, 27, 28], interstitial fibrosis, second-
ary glomerulosclerosis, and tubular atrophy are hallmarks of
ESRD of any etiology. Because NPH is typically first suspected
in advanced stages of CKD when damage is extensive, histol-
ogy is often inconclusive and of limited diagnostic value, while
it is an invasive procedure for the patient that carries an even
higher risk for complications in advanced stages of chronic
kidney disease [29]. Another patient with NPH (29:65) present-
ed with polydipsia and polyuria at age 7, when the estimated
glomerular filtration rate (eGFR) was normal. At age 15, she
presented with fatigue for several weeks and was diagnosed
with renal failure. These examples illustrate that a potential
treatment window exists if initial signs of NPH are recognized.
In addition, early genetic testing and identification of bio-
markers that are more sensitive than eGFR could benefit timely
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detection and adequate supportive treatment, including treat-
ment of anemia and hypertension [20], in NPH-RC patients.
Persistent fatigue and muscle complaints were identified as
new presenting symptoms of NPH that should prompt evalu-
ation of kidney function. Muscle complaints could represent
musculoskeletal pains, a uremic symptom which is highly
prevalent in patients with CKD [30], or could result from
electrolyte disturbances (for example low serum magnesium).
Electrolyte data was not available for the respective patients at
the time of symptoms onset. Hypertension was an initial sign
in 21% of patients (n = 5), including one patient who currently
has CKD stage 2. This finding contradicts literature that sug-
gests that hypertension is a late finding in NPH because of
renal salt wasting [31]. However, because of the diagnostic
delay in NPH, hypertension could be an initial sign indicating
advanced CKD. Diagnostics of NPH can be challenging, even
when a causal mutation in a ciliopathy-associated gene has
been detected, because other kidney diseases can mimic the
NPH phenotype [11]. We detected homozygous mutations in
the ciliary gene TTC21B in four patients from one family with
a renal ciliopathy phenotype comprising renal insufficiency
and retinitis pigmentosa (Supplementary Results 1).
However, early proteinuria indicated glomerular kidney dis-
ease, which has also been described in patients with TTC21B
mutations [32, 33], instead of NPH. Consequently, knowledge
of the NPH phenotype is critical, not only for early detection
but also for proper distinction of NPH from phenocopies.
Eight out of 13NPH-RC patients that were genetically tested
in this study remained unsolved, consistent with the less than
50%mutation detection rate described in literature [11, 12]. We
detected single heterozygous variants in ciliopathy-associated
genes in two patients (15%). A patient with Joubert syndrome
(3:36) carried heterozygous variants in CEP290 and KIF7.
Another patient with Joubert syndrome (2:35) carried a hetero-
zygous predicted deleterious variant in CEP164. Sequencing
and deletion/duplication analysis usingYouMAQdid not reveal
additional variants on the second allele. Single heterozygous
mutations in ciliopathy-associated genes have been frequently
reported in literature [12, 34]. Possible explanations are that
variants on the second allele were missed by the respective
sequencing techniques, for example because of intronic locali-
zation, that detected heterozygous variants represent genetic
modifiers, or that detected variants are unrelated to the pheno-
type. We also identified a heterozygous predicted deleterious
variant in the previously described candidate ciliary gene NINL
in a patient with isolated NPH (29:65). NINL, or ninein-like
protein, colocalizes with CC2D2A at the base of the cilium. A
heterozygous variant in NINL has been proposed to act as a
genetic modifier in a patient with a severe form of Joubert
syndrome caused by mutations in CC2D2A [35]. Further re-
search is required to elucidate the role of NINL in NPH-RC.
We did not find statistically significant genotype-
phenotype correlations as a result of the size and heterogeneity
of our cohort. However, patterns can be discerned that support
previously published gene-phenotype associations. Patients
with biallelic NPHP1 and NPHP4 mutations exhibited isolat-
ed NPH more frequently (in 75 and 100%, respectively) com-
pared to NPH patients with other gene defects, which is in line
with previous literature [6, 7, 14]. Visual impairment was the
most common extrarenal manifestation in patients with
NPHP1 mutations, present in 19%. Neurologic symptoms
(oculomotor apraxia and developmental delay) were reported
less frequently than in literature (n = 1; 7%) [6, 7, 14].
Interestingly, we found an older median age of symptom onset
of 16 years (range 8–24 years) and a lower rate of CKD pro-
gression in patients with NPHP4 mutations compared to pa-
tients with other gene defects, corroborating the findings of
König et al. [6]. Larger, well-phenotyped cohorts of NPH-RC
patients are required to strengthen genotype-phenotype corre-
lations, which is essential for providing an accurate prognosis
to patients. To this end, the Nephronophthisis Registry de-
scribed here can be combined with other international cohorts.
In conclusion, this study provides a comprehensive analy-
sis of renal and extrarenal ciliopathy phenotypes in a cohort of
40 Dutch patients with NPH-RC. Persistent fatigue, polyuria,
hypertension, and muscle cramps were identified as initial
signs and symptoms of NPH that should prompt timely eval-
uation of renal function. Symptom onset can occur in adult-
hood, which supports continuation of presymptomatic kidney
function monitoring in patients with a syndromic ciliopathy
until at least age 30 years. Our findings confirm that increased
echogenicity is a more prevalent finding than cysts on renal
ultrasound in NPH-RC patients and that mutations in NPHP4
are associated with slower kidney disease progression and a
lower prevalence of extrarenal manifestations than mutations
in other NPH-associated genes. Ultimately, improving recog-
nition of NPH and associated phenotypes will enable adequate
surveillance and clinical care for patients with NPH-RC.
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